Airbion: German company challenges COVID-19 viruses and other ultrafine particles

- (COVID-19) Viruses, bacteria and allergens are removed from the air by means of novel technologies without filters and without releasing noxious substances

- Strong team including renowned international scientists, industry managers and Business Angels expedites international roll-out of the VAPUR technology by Airbion

- After a five-year development period: unique, patented combination of ultrasonic waves, UV light and heat as a guarantor for an outstanding effectiveness

- Production "Made in Germany" started - already more than 2,500 devices ordered

- Target group: offices, restaurants, medical practices, and private households

- Market for air purification solutions currently at around USD 13.4 billion p. a. in Europe alone, with growth rates of more than 8 percent p. a.

Rellingen / Gronau, 1 March 2021 - Airbion GmbH, a provider of innovative air purification technology and devices, presents with the Airbion One the worldwide first device in a handy format, which is able to remove ultrafine particles such as viruses from the air without any contaminants from the air. Fine dust, allergens and e.g. COVID-19 (SARS-CoV-2) are eliminated safely and completely in this way. Consequently, Airbion can make a substantial contribution towards the containment of the current COVID-19 pandemic.

Now launch of marketing after five-year development by team of scientists

Over a period of five years, the developer team around Professor Dr. Gregor Luthe has worked on the development of the technology and its implementation to reach market maturity. On 1 March 2021 Airbion now starts with the delivery of the first devices. Apart from Professor Luthe, who enjoys an excellent international reputation as nanotechnologist and chemist and has been teaching and researching at universities in Europe and the USA, experienced industry managers and renowned German Business Angels founded the company. Their objective: Make a significant contribution to clean respiratory air with the unique patented technology of Airbion. The production takes place at the corporate production site in Gronau (North Rhine-Westphalia). The final assembly of the devices is currently already running at full speed. More than 2,500 binding orders - mainly from the USA - have already been received. The first 1,000 devices will be delivered from today onwards.

Novel, patented VAPUR technology removes viruses, bacteria and ultrafine particles

The VAPUR technology developed by Professor Luthe and his team, with comprehensive patent protection, combines ultrasound, UV-C waves and heating to render ultrafine particles, viruses and bacteria suspended in the air harmless. Through the ultra-heating of these microparticles in the air stream, organic components are killed and denatured, through UV-C waves the RNA of bacteria and viruses is destroyed and ultrasound ensures that the virus shells are broken apart and the ultrafine particles are clumped. For humans, the air purification is not perceivable and completely harmless. No toxic chemicals are used and no toxic substances, such as ozone, are released. The current table-top device can purify around 90 m³ of ambient air per hour. A large device with a purification performance of around 400 m³ air per hour is in its final development and will probably be launched during the second half of 2021.

Experts attest unique principle of operation, also compared to ULPA and HEPA filters

Independent experts confirm that the VAPUR technology and the technology solutions of Airbion have a unique, positive effect. The renowned consulting company BlueXPRT attests in a current expert report: "The VAPUR technology is provably suited to eliminate ultrafine particles and hence COVID-19 viruses from the respiratory air. Even the most modern methods of particle removal were not able to cope with this so far." The Institute for Energy and Environmental Technology (IUTA), Duisburg, has certified in respect of Airbion: "The device provably kills SARS-CoV-2 by aggregation and UV-C irradiation." Aerosol Research and Engineering Labs, Inc. from the USA reaches the following conclusion in an impact study on a viral and a bacterial level: "In the field of virus killing an effectiveness of 99.943 was reached. The device reduces 99.831% of the bacterium Staphylococcus epidermidis [.] this device could hence reduce the risk of pulmonary infections". Consequently, Airbon clearly distinguishes itself from the existing filter solution, such as ULPA and HEPA filters. Many dangerous viruses, bacteria and particles are not completely captured by the existing commercial devices and, in addition, contaminated filters have to be replaced on a regular basis. As far as total costs are concerned, the VAPUR technology and the Airbion devices are hence superior to the conventional filter solutions.

Broad target group and high sales revenue objectives beyond COVID-19 / Fine dust as a global problem

Airbion has set itself ambitious goals for the coming years. In the medium-term the provider of innovative air purification technology is striving with the Airbion devices for annual sales revenues of more than EUR 100 million. This expectation is underpinned by the high demand due to the current COVID-19 pandemic and a constantly increasing need for clean air against the backdrop of increasing (ultra) fine dust contamination in the worldwide metropolises. According to expert assessments, around 4.5 million people die every year of the sequelae of fine dust. Cancer, cardiovascular diseases and allergies are triggered by ultrafine particles, and the global economic damage is huge, too: It is estimated to amount to USD 2.9 trillion per year. The market for air purification has, therefore, a correspondingly growing importance. In Europe alone, analytical studies have determined that USD 13.4 billion are annually spent on air purification. The annual growth is estimated to amount to an average of more than 8 percent during the coming seven years. In this connection it needs to be taken into account that these estimates by market experts still date back to the time before the COVID-19 pandemic. The Airbion devices are suited for use in offices, medical practices, stores and shops, schools, fitness studios and last, but not least in private households - because clean air for healthy breathing is an issue in almost all life situations.

Sale of Airbion devices through different channels

For the sale of the novel Airbion devices, the company relies on several channels. Apart from direct marketing to final customers through its own website and social media channels, an external sales structure for B2B customers has been integrated. The focus is on healthcare, but other commercial customers are addressed as well.

Founder with major goals - Airbion as a game changer in air purification

Professor Dr. Gregor Luthe, the inventor of the VAPUR technology and Chief Scientific Officer (CSO) of Airbion: "We have a unique technology which has an extremely high effectiveness. As a rule, conventional filter solutions cannot achieve this. In this connection we can do completely without chemistry and waste disposal issues for contaminated filters. In the current COVID-19 pandemic our solution is a strong contribution to the creation of clean virus-free air at places where people meet, work and enjoy their leisure time. Here, we create clean air for breathing. With Airbion we make a contribution to allow for a more rapid and sustainable return to a normalized life. We intend to launch a device for large spaces based on the VAPUR technology and, moreover, we work on mobile solutions to be carried along in busses, trains and planes. But our solution remains of course highly necessary beyond the pandemic, because the purification of contaminated air by removing ultrafine particles plays a growing role in our industrialized world. The large number of advance orders did, therefore, not surprise me. I am glad that after many years of research and development work, we can now deliver and start a broad marketing of the Airbion devices. Airbion is a game changer for air purification - for the benefit or our device users, the environment and our investors."

About Airbion

Airbion is a provider of innovative technologies and devices with which respiratory and ambient air are purified by removing ultrafine particles and viruses. To do so, the patented, unique VAPUR technology is used which combines ultrasonic waves, UV-C waves and ultraheating. In this way, Airbion can remove ultrafine particles, viruses and bacteria from the air without contaminants and is clearly superior to conventional filter solutions. Airbion was founded by scientists and top industry managers. The company has its head office in Rellingen; the Airbion devices have been produced and internationally distributed in Gronau (North Rhine-Westphalia) since 2020. More information available on

Press Contact

edicto GmbH

Ralf Droz/ Svenja Liebig

Eschersheimer Landstraße 42

60322 Frankfurt am Main

Phone: +49 (0) 69 905505-54

Mail: